An experimental drug called KCL-286 repaired DNA damage and reduced brain inflammation in mice with Alzheimer's-like changes, targeting several early disease pathways at once rather than focusing only on amyloid or tau proteins.
The research
Neuroscientists at King's College London, led by Professor Jonathan Corcoran and project manager Dr Maria Goncalves, tested KCL-286 in a mouse model of Alzheimer's disease. The drug, originally developed for spinal cord injury, works by activating a protein in the retinoic acid pathway, which helps the body process vitamin A. Earlier work by the same team identified shared molecular pathways between acute spinal cord injury and Alzheimer's disease, suggesting the drug might also repair Alzheimer's-related damage in neurons.
KCL-286 had previously shown an ability to repair DNA double-strand breaks in studies of neuropathic pain. In the new study, it promoted repair of the same type of breaks in Alzheimer's model mice and reduced inflammation. "DNA double-strand breaks are like a rope snapping completely in two, rather than just fraying at the edges," said Professor Corcoran. "We found that KCL-286 promotes repair of these breaks, allowing us to target a key feature of Alzheimer's disease."
The study, published in 2026, used a mouse model rather than human participants, so results cannot yet be directly translated to people. However, KCL-286 has already completed Phase 1 human safety and tolerability trials for another condition, which could speed up future clinical testing in Alzheimer's. "KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 human safety and tolerability trials," Corcoran noted. "This will dramatically cut down the traditional multi-year timeline required for new drug development."
Why it matters
Most approved Alzheimer's treatments target amyloid-beta, and their clinical benefits have been limited. This study points to two earlier processes, DNA damage and inflammation, that appear in the earliest stages of the disease. By addressing multiple mechanisms at once, drugs like KCL-286 could potentially slow progression rather than only easing symptoms. For anyone concerned about long-term brain health, the research reinforces that cognitive decline involves many intertwined biological pathways, not a single culprit. It also highlights how existing drugs can find new purposes when scientists compare molecular signatures across different conditions.
What you can do
- Stay physically active: regular exercise supports DNA repair mechanisms and reduces inflammation throughout the body, including the brain.
- Eat a diet rich in vitamin A sources (carrots, sweet potatoes, leafy greens) and anti-inflammatory foods like fatty fish, berries, and nuts.
- Keep your brain challenged with novel learning, puzzles, and social engagement, which may help build cognitive reserve.
- Talk to your doctor about any memory concerns, and ask about clinical trials if you have a family history of Alzheimer's.
Source: ScienceDaily Mind & Brain
Curious about your own brain? Take our free adaptive IQ test or try 306 brain training levels.